Informação da revista
Vol. 38. Núm. 12.
Páginas 881-882 (Dezembro 2019)
Baixar PDF
Mais opções do artigo
Vol. 38. Núm. 12.
Páginas 881-882 (Dezembro 2019)
Editorial comment
DOI: 10.1016/j.repc.2020.01.008
Open Access
Predicting contrast-induced nephropathy in patients with acute myocardial infarction: Can it be avoided?
Previsão de nefropatia induzida por contraste em pacientes com enfarte agudo do miocárdio: pode ser evitado?
Manuel de Sousa Almeida
Unidade de Intervenção Cardiovascular, Hospital de Santa Cruz, Carnaxide, Portugal
Informação do artigo
Texto Completo
Baixar PDF
Texto Completo

Copeptin, the C-terminal part of pro-arginine vasopressin, has been extensively analyzed in different settings as a marker of acute severe biological stress, and has been linked to worse heart- and kidney-related clinical outcomes.1

In their article published in the current issue of the Journal, Yildirim and Cabbar2 hypothesized that copeptin is a sensitive biomarker to predict acute kidney injury after primary percutaneous coronary intervention (PCI) and found an association between copeptin levels and contrast-induced nephropathy (CIN) in patients with ST-elevation myocardial infarction (STEMI). They conclude that copeptin level at hospital admission has added value as an independent predictor of CIN.

In an era when older and sicker patients, with more complex heart disease, are being treated percutaneously with more complex procedures, it is fair to assume that more contrast media will be used. Even if currently available contrast media are safer than previous types, in older patients with glomerular filtration rate below 40 ml/min, CIN should be always an important concern for every interventionalist. It can affect as many as 25% of STEMI patients treated with primary PCI,3 it is the third most common cause of acute renal failure in hospitalized patients,4 and has a major impact on patient prognosis as well as on morbidity and quality of life.5,6 These reasons are sufficient to bring CIN to the forefront of our concerns every time we decide on a contrast-based procedure, whether diagnostic or therapeutic.

The clinical value of Yildirim and Cabbar's results in preventing CIN in the setting of STEMI is doubtful, since primary PCI is an emergent procedure in which the main concern is to obtain TIMI 3 flow in the culprit lesion as soon as possible, regardless of previous blood marker results, which are usually not available. But the availability of quick results from point of care testing7 may in the future be helpful in choosing safer treatment strategies for STEMI, as in the current controversy surrounding multivessel PCI in STEMI,8 in which it could lead to safer procedures, postponing non-culprit multivessel PCI, if possible.

The question is whether such results also apply to other clinical settings such as non-STEMI or even elective coronary procedures. It is reasonable to assume that they may, although further research is certainly needed. In such scenarios, upfront knowledge of an increased risk for CIN could be an important factor in the decision-making process, avoiding further acute kidney injury and CIN, as the real incidence of CIN in these patients may be underestimated due to the fact that they are discharged early, long before the 3-4 day peak incidence of CIN.9

Yildirim and Cabbar have provided a tool to predict CIN after PPCI. Whether it has a better performance than the current score by Mehran et al.3 is still unknown, but is certainly simpler, a good predictor of adherence by interventionalists.

Conflicts of interest

The author has no conflicts of interest to declare.

K. Yalta, T. Yalta, N. Sivri, et al.
Copeptin and cardiovascular disease: a review of a novel neurohormone.
Int J Cardiol, 167 (2013), pp. 1750-1759
E. Yildirim, A.T. Cabbar.
Association between copeptin and contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction.
Rev Port Cardiol, 38 (2019),
R. Mehran, E.D. Aymong, E. Nikolsky, et al.
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.
J Am Coll Cardiol, 44 (2004), pp. 1393-1399
K. Nash, A. Hafeez, S. Hou.
Hospital-acquired renal insufficiency.
Am J Kidney Dis, 39 (2002), pp. 930-936
C.S. Rihal, S.C. Textor, D.E. Grill, et al.
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention.
Circulation, 105 (2002), pp. 2259-2264
P. Aubry, G. Brillet, L. Catella, et al.
Outcomes, risk factors and health burden of contrast-induced acute kidney injury: an observational study of one million hospitalizations with image-guided cardiovascular procedures.
BMC Nephrol, 17 (2016), pp. 167
M. Vafaie, M. Biener, M. Mueller, et al.
Addition of copeptin improves diagnostic performance of point-of-care testing (POCT) for cardiac troponin T in early rule-out of myocardial infarction – a pilot study.
Int J Cardiol, 198 (2015), pp. 26-30
M. de Sousa Almeida.
“Unsuitable for PCI...” Multivessel primary PCI. But for whom?.
Rev Port Cardiol, 33 (2014), pp. 75-77
I. Goldenberg, S. Matetzky.
Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies.
CMAJ, 172 (2005), pp. 1461-1471
Copyright © 2020. Sociedade Portuguesa de Cardiologia
Revista Portuguesa de Cardiologia

Receba a nossa Newsletter

Opções de artigo
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.